Want to see APRE full AI Analyst Report?
APRE Stock Chart & Stats
$0.63
<$0.01(0.16%)
At close: 4:00 PM EDT
$0.63
<$0.01(0.16%)
Day’s Range― - ―
52-Week Range$0.55 - $1.70
Previous Close$0.61
Volume18.33K
Average Volume (3M)55.77K
Market Cap
$8.06M
Enterprise Value$2.40
Total Cash (Recent Filing)$41.23M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.08
Next Earnings
Nov 05, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.29
Shares Outstanding12,591,136
10 Day Avg. Volume84,633
30 Day Avg. Volume55,770
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.43
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.73Price Target Upside492.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.69
Revenue Forecast (FY)$1.07M
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetThe absence of debt limits interest obligations and refinancing exposure, giving Aprea greater flexibility to direct available capital toward clinical programs. This reduces solvency risk while the company remains pre-commercial and dependent on development execution.
Extended Cash RunwayThe strengthened cash position and stated runway provide time to advance APR-1051 trials without an immediate financing requirement. This supports sustained development activity and reduces near-term disruption risk, although future funding may still be needed.
APR-1051 Clinical ProgressEarly clinical activity and broader trial plans improve the pipeline’s potential commercial relevance if results persist. Expansion across biomarker-defined solid tumors and combination settings could diversify future indications and increase the value of development success.
Bears Say
No Sustainable RevenueAprea has no established commercial revenue stream, leaving its business model dependent on clinical milestones and eventual product approval. Until a candidate reaches commercialization, operating performance will remain highly uncertain and vulnerable to development setbacks.
Persistent Cash-Burning LossesOngoing operating losses translate into substantial cash consumption, limiting internal funding capacity. Even with the current runway, continued negative cash flow means Aprea must achieve clinical progress or raise capital to sustain its pipeline over the longer term.
Capital Instability And Pipeline ConcentrationVolatile equity levels indicate that financing and accumulated losses have materially affected capital stability, creating dilution risk. Pausing ATRN-119 monotherapy also concentrates strategic and clinical dependence on APR-1051 and its trial outcomes.
Aprea Therapeutics News
APRE FAQ
What was Aprea Therapeutics Inc’s price range in the past 12 months?
Aprea Therapeutics Inc lowest stock price was $0.55 and its highest was $1.70 in the past 12 months.
What is Aprea Therapeutics Inc’s market cap?
Aprea Therapeutics Inc’s market cap is $8.06M.
When is Aprea Therapeutics Inc’s upcoming earnings report date?
Aprea Therapeutics Inc’s upcoming earnings report date is Nov 05, 2026 which is in 73 days.
How were Aprea Therapeutics Inc’s earnings last quarter?
Aprea Therapeutics Inc released its earnings results on Aug 12, 2026. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.178 by $0.108.
Is Aprea Therapeutics Inc overvalued?
According to Wall Street analysts Aprea Therapeutics Inc’s price is currently Undervalued.
Does Aprea Therapeutics Inc pay dividends?
Aprea Therapeutics Inc does not currently pay dividends.
What is Aprea Therapeutics Inc’s EPS estimate?
Aprea Therapeutics Inc’s EPS estimate is -0.07.
How many shares outstanding does Aprea Therapeutics Inc have?
Aprea Therapeutics Inc has 12,591,136 shares outstanding.
What happened to Aprea Therapeutics Inc’s price movement after its last earnings report?
Aprea Therapeutics Inc reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.178. Following the earnings report the stock price went up 3.485%.
Which hedge fund is a major shareholder of Aprea Therapeutics Inc?
Currently, no hedge funds are holding shares in APRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aprea Therapeutics Inc
Aprea Therapeutics, Inc. (APRE) is a clinical-stage biopharmaceutical company focused on developing novel cancer therapeutics. The company’s pipeline has centered on small-molecule drug candidates intended to target tumor biology (historically including programs aimed at p53-related pathways) and other oncology approaches, with activities primarily in research and clinical development rather than commercial product sales.
APRE Stock 12 Month Forecast
Average Price Target
$3.73
▲(492.59% Upside)
Technical Analysis
Ownership Overview
6.39% Insiders
0.84% Mutual Funds
16.16% Other Institutional Investors
76.41% Public Companies and
Individual Investors